Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Patient access to medication. | Image Credit: Supatman - stock.adobe.com
Addressing Patent Hurdles, Payer Barriers, and Interchangeability

November 22nd 2024

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

Health care expenses. | Image Credit: izzuan - stock.adobe.com
Financial Incentives Drive Biosimilar Adoption in Japan

November 20th 2024

FDA logo and website | Image credit: Postmodern Studio - stock.adobe.com
FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges

November 6th 2024

Retinal condition | Image Credit: Yakobchuk Olena - stock.adobe.com
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD

October 30th 2024

health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com
Exploring the Complexities of Biosimilars and Interchangeability

October 30th 2024

Continuing Medical Education
View All
November 26th 2024

Managed Care Pharmacy: A Plan for the Future and How Pharmacists Are Leading the Way

0.5 Credits / General Pharmacy

More News

Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars
October 15th 2019

Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars

Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.
Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology
September 29th 2019

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.
Site Logo
September 27th 2019

Biosimilar Insulin Could Offer Patients Cost-Saving Options

Sara Karlovitch
From the Center for Biosimilars®, a discussion on giving patients new, less expensive alternatives for managing diabetes.
Site Logo
September 27th 2019

How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?

Kelly Davio
From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.
AJMC® in the Press, September 6, 2019
September 6th 2019

AJMC® in the Press, September 6, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
This Week in Managed Care: August 9, 2019
August 9th 2019

This Week in Managed Care: August 9, 2019

This week, the top managed care stories included CMS giving chimeric antigen receptor T-cell payments a boost; a US task force announcing that those at risk for pancreatic cancer should be screened; FDA revealing Novartis withheld data about a high-cost gene therapy.
AJMC® in the Press, August 9, 2019
August 9th 2019

AJMC® in the Press, August 9, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Site Logo
July 16th 2019

Biosimilars: ASCO 2019

Kelly Davio
Research on biosimilars presented at the 2019 Annual Meeting of the American Society of Clinical Oncology.
AJMC® in the Press, June 21, 2019
June 21st 2019

AJMC® in the Press, June 21, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Site Logo
May 23rd 2019

Biosimilar Experts Give Highlights of US Uptake Issues

Allison Inserro
During ISPOR 2019 annual meeting, a session featured biosimilar experts who reviewed the current state of affairs and various challenges related to uptake, while also sounding some notes of optimism.
What We're Reading: Measles Quarantines; Roche's Cancer Drug Competition; Blood Pressure Targets for T2D
April 29th 2019

What We're Reading: Measles Quarantines; Roche's Cancer Drug Competition; Blood Pressure Targets for T2D

AJMC Staff
Nearly 700 people at California State University and the University of California, both in Los Angeles, were still in quarantine over the weekend after possibly being exposed to measles; the world’s largest seller of cancer drugs, pharma company Roche Holding AG, will lose its top spot with competition from lower-cost drugs, namely biosimilars; findings from a new study showed that blood pressure regulation at or below 130/80 mm Hg lowered the risk of heart attack, stroke, or other complications in patients with type 2 diabetes (T2D).
Site Logo
April 17th 2019

Conference Coverage: NCCN Policy Updates

Jaime Rosenberg Mary Caffrey Laura Joszt, MA
Policy updates from the National Comprehensive Cancer Network's annual meeting.
AJMC® in the Press, April 5, 2019
April 5th 2019

AJMC® in the Press, April 5, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Dr Ali McBride Discusses the Role of Biosimilars in Oncology
March 25th 2019

Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.
Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved
March 24th 2019

Dr Gary Lyman Sees Knowledge of Biosimilars in Cancer Has Improved

Although there is still a need for more education around the use of biosimilars in cancer, it seems oncologists have become more knowledgeable in the past few years, said Gary H. Lyman, MD, MPH, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance.
AJMC® in the Press, March 22, 2019
March 22nd 2019

AJMC® in the Press, March 22, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
AJMC® in the Press, March 8, 2019
March 8th 2019

AJMC® in the Press, March 8, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
What We're Reading: Canada Sets Biologics Naming Rules; Heath Trackers and Employee Privacy; IVF and Embryos
February 18th 2019

What We're Reading: Canada Sets Biologics Naming Rules; Heath Trackers and Employee Privacy; IVF and Embryos

AJMC Staff
Health Canada announced that all biologics, including biosimilars, will be identified by their brand names and nonproprietary names without the addition of a product-specific suffix; a boom in the use of connected health and fitness monitors that are connected to insurance plans and employers is providing an increasingly valuable source of workforce health intelligence, raising privacy concerns, and adding a new dimension to the worker-employer relationship; as the number of spare embryos from in vitro fertilization rises, giving birth with donated embryos is becoming more popular, although many of the agencies that provide donated embryos are supported by federal funds and restrict whom they help.
What We're Reading: Drug Pricing Proposals; Idaho Medicaid Expansion; Business and Biosimilars
January 25th 2019

What We're Reading: Drug Pricing Proposals; Idaho Medicaid Expansion; Business and Biosimilars

AJMC Staff
Presumed 2020 presidential candidates are trying to stake a claim to one of healthcare’s main concerns—surging prescription drug prices; enrollment in Idaho's health insurance exchange is expected to drop by 20% due to Medicaid expansion; employer groups can help overcome barriers, such as patient fears and misinformation, and create confidence about using biosimilars.
Dr Robert Rifkin on Lack of Education Surrounding Biosimilars
January 22nd 2019

Dr Robert Rifkin on Lack of Education Surrounding Biosimilars

Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.
Site Logo
January 18th 2019

Cost of Care: Biosimilars

Updates from the annual ASH meeting, December 2018.
What We're Reading: Faulty Drugs; Biosimilar Awareness; Maine Implements Medicaid
January 4th 2019

What We're Reading: Faulty Drugs; Biosimilar Awareness; Maine Implements Medicaid

AJMC Staff
A review of thousands of FDA inspection records, recalls, warning letters, and lawsuits showed how drugs that are poorly manufactured or contaminated can reach patients; biosimilars have the potential to deliver substantial savings to the healthcare system, but only insofar as they are adopted and used in clinical practice; Maine’s new Democratic Governor, Janet Mills, ordered the state to implement Medicaid expansion with an executive order, calling for state health officials to make the necessary changes and work with the Trump administration.
The Key Biosimilars Developments of 2018
December 21st 2018

The Key Biosimilars Developments of 2018

Kelly Davio
The year 2018 was a banner year for biosimilars, with the number of FDA-approved biosimilar products nearly doubling, and with major policy, business, and regulatory developments that moved the biosimilars marketplace forward. Here are 5 of the top developments in biosimilars for the past year, as reported by The Center for Biosimilars®, a sister site of The American Journal of Managed Care®.
Site Logo
December 12th 2018

Biosimilars Updates

Kelly Davio Samantha DiGrande
What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption
December 12th 2018

What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption

AJMC Staff
The House has passed a bill that would support state efforts to investigate pregnancy-related deaths and research how to prevent future deaths; a column in The New York Times examined 4 specific drug pricing policies and had 3 health policy experts weigh in on what the outcomes of implementing these policies could be; despite the benefits of using biosimilar filgrastim, the United States has lagged behind other countries in adopting the therapy.
Site Logo
December 6th 2018

Managing Costs and Advancements in Biosimilars

https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-supplement-managing-costs-and-advancements-in-biosimilars
AJMC® in the Press, November 30, 2018
November 30th 2018

AJMC® in the Press, November 30, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
What We're Reading: Generic EpiPen Cost; Amazon's Medical Software; European Report on Curbing Spending
November 28th 2018

What We're Reading: Generic EpiPen Cost; Amazon's Medical Software; European Report on Curbing Spending

AJMC Staff
A generic competitor to the EpiPen will not cost any less than the version that is already on the market; a new service from Amazon will use machine learning to pull key information from patient records; a new report from the European Commission has noted that generic and biosimilar products will be key to curbing wasteful spending in healthcare.
Site Logo
November 20th 2018

Current Market and Regulatory Landscape of Biosimilars

Valkal Bhatt, PharmD
Site Logo
November 20th 2018

Optimizing Use and Addressing Challenges to Uptake of Biosimilars

Molly Billstein Leber, PharmD
<1
...
8910111213141516
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo